Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Treasury Shares (2016 - 2025)

Syndax Pharmaceuticals has reported Treasury Shares over the past 7 years, most recently at $2.6 million for Q4 2025.

  • Quarterly results put Treasury Shares at $2.6 million for Q4 2025, up 100.72% from a year ago — trailing twelve months through Dec 2025 was $2.6 million (up 100.72% YoY), and the annual figure for FY2025 was $2.6 million, up 100.72%.
  • Treasury Shares for Q4 2025 was $2.6 million at Syndax Pharmaceuticals, up from $1.3 million in the prior quarter.
  • Over the last five years, Treasury Shares for SNDX hit a ceiling of $2.6 million in Q4 2025 and a floor of $132333.0 in Q4 2021.
  • Median Treasury Shares over the past 5 years was $392288.0 (2023), compared with a mean of $634897.7.
  • Biggest five-year swings in Treasury Shares: soared 615.31% in 2021 and later surged 52.89% in 2023.
  • Syndax Pharmaceuticals' Treasury Shares stood at $132333.0 in 2021, then soared by 69.87% to $224788.0 in 2022, then surged by 131.08% to $519436.0 in 2023, then skyrocketed by 151.06% to $1.3 million in 2024, then skyrocketed by 100.72% to $2.6 million in 2025.
  • The last three reported values for Treasury Shares were $2.6 million (Q4 2025), $1.3 million (Q4 2024), and $519436.0 (Q4 2023) per Business Quant data.